{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:15:57Z","timestamp":1782753357684,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejpn.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T09:33:04Z","timestamp":1654421584000},"page":"103-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-250X","authenticated-orcid":false,"given":"Katarzyna","family":"Kotulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Chmielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mazurkiewicz-Be\u0142dzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Tomaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pierzchlewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rabczenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0209-4103","authenticated-orcid":false,"given":"\u0141ukasz","family":"Przys\u0142o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Biedro\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Czy\u017cyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Steinborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Pietruszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4522-8415","authenticated-orcid":false,"given":"Leszek","family":"Bo\u0107kowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Cichosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Dudzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Gadowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"M\u0142ynarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142aw","family":"Jasi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Masztalerz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Kempisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-1914","authenticated-orcid":false,"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpn.2022.06.001_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ejpn.2022.06.001_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ejpn.2022.06.001_bib3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","article-title":"The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ejpn.2022.06.001_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.ejpn.2022.06.001_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"9","key":"10.1016\/j.ejpn.2022.06.001_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ejpn.2022.06.001_bib7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2022.06.001_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2022.06.001_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-021-01771-y","article-title":"Observation of the natural course of type 3 spinal muscular atrophy: data from the Polish registry of spinal muscular atrophy","volume":"16","author":"Lusakowska","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ejpn.2022.06.001_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.ejpn.2022.06.001_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1090-3798(99)80012-9","article-title":"Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype","volume":"3","author":"Dubowitz","year":"1999","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2022.06.001_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejpn.2022.06.001_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10063","key":"10.1016\/j.ejpn.2022.06.001_bib14","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ejpn.2022.06.001_bib15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ejpn.2022.06.001_bib16","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ejpn.2022.06.001_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.ejpn.2022.06.001_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/dmcn.14412","article-title":"Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen","volume":"62","author":"Aragon-Gawinska","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2022.06.001_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J.\u00a0Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.ejpn.2022.06.001_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland","volume":"55","author":"Modrzejewska","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.ejpn.2022.06.001_bib21","article-title":"Minimal clinically important differences in motor function in patients with infantile-onset spinal muscular atrophy: results from the phase 3 endear trial","volume":"25","author":"Stull","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.ejpn.2022.06.001_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nmd.2020.12.006","article-title":"Nusinersen treatment of older children and adults with spinal muscular atrophy","volume":"31","author":"Konersman","year":"2021","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.ejpn.2022.06.001_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.ejpn.2022.06.001_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function","volume":"28","author":"Pane","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"18","key":"10.1016\/j.ejpn.2022.06.001_bib25","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.06.001_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2022.06.001_bib27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul. Disord."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:39:53Z","timestamp":1761071993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379822000885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":27,"alternative-id":["S1090379822000885"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.06.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}